MAYO CLINIC LABORATORIES

1-800-533-1710

BHYPS

Hypersensitivity Pneumonitis Panel, Immunoglobulin G, Serum

Patient ID	Patient Name		Birth Date	Sex	Age
SA00179591	VALIDATIONSOFT, TESTING BHYPS		1992-02-15	M	34
Order Number	**Client Order Number**	**Ordering Physician**	**Report Notes**		
SA00179591	SA00179591	CLIENT,CLIENT			
Account Information		**Collected**			
C7028846 DLMP Rochester		19 Mar 2026 06:00			

Hypersensitivity Pheum Panel,IgG, S

Alternaria alternata, IgG Ab — SDL

⚠ 100.0 mg/L High

Reference Value ≤ 19.0 mg/L

Aspergillus fumigatus, IgG Ab — SDL

⚠ 150.0 mg/L High

Reference Value ≤ 102.0 mg/L

Aureobasidium pullulans, IgG Ab — SDL

⚠ 160.0 mg/L High

Reference Value ≤ 16.0 mg/L

Laceyella sacchari, IgG Ab — SDL

⚠ 170.0 mg/L High

Reference Value ≤ 45.0 mg/L

Micropolyspora faeni, IgG Ab — SDL

⚠ 180.0 mg/L High

Reference Value ≤ 6.0 mg/L

Penicillium chrysogenum, IgG Ab — SDL

⚠ 190.0 mg/L High

Reference Value ≤ 94.0 mg/L

Phoma betae, IgG Ab — SDL

⚠ 191.0 mg/L High

Reference Value ≤ 16.0 mg/L

Trichoderma viride, IgG Ab — SDL

⚠ 192.0 mg/L High

Reference Value ≤ 16.0 mg/L

Hypersensitivity Interpretation — [1] SDL

See Interpretation

Antibody levels greater than the reference range indicate that the patient has been immunologically sensitized to the antigen or a related antigen. Therefore, the significance of an elevated antibody response is dependent on a combination of patient's clinical history, HRCT (high-resolution computed tomography) scan findings, pathological examination, and certain risk factors (e.g., environmental, and occupational determinants). Results must be interpreted as a component of a comprehensive diagnostic evaluation and known limitations of hypersensitivity tests.

The test method utilizes the fluorescence enzyme immunoassay (FEIA) on the Phadia ImmunoCAP 250. Values obtained using the same test system or different assay methods cannot be used interchangeably. Alternative reference values established utilizing the same reagents or test system may be influenced by the characteristics of the local cohorts and environmental exposures.

Received: 19 Mar 2026 15:09 **Reported:** 19 Mar 2026 15:09

Laboratory Notes

[1] This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
SDL	Mayo Clinic Laboratories - Rochester Superior Drive	3050 Superior Drive NW, Rochester MN 55905	Nikola Baumann Ph.D.	24D1040592